Stevens Capital Management LP Invests $1.16 Million in Amgen Inc. $AMGN

Stevens Capital Management LP acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,536 shares of the medical research company's stock, valued at approximately $1,157,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Board of the Pension Protection Fund acquired a new stake in Amgen in the fourth quarter valued at $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen during the 4th quarter valued at about $33,000. Cloud Capital Management LLC acquired a new position in shares of Amgen during the 3rd quarter valued at about $34,000. Ares Financial Consulting LLC purchased a new position in shares of Amgen during the 4th quarter worth about $34,000. Finally, Saranac Partners Ltd purchased a new position in shares of Amgen during the 3rd quarter worth about $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company's stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
• Neutral Sentiment: Erste Group reaffirmed a "hold" rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
• Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title

Amgen Stock Up 1.8%

AMGN opened at $329.59 on Wednesday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm has a 50 day moving average price of $357.16 and a 200 day moving average price of $341.35. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26. The company has a market cap of $177.87 billion, a PE ratio of 22.94, a price-to-earnings-growth ratio of 3.08 and a beta of 0.44.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. During the same period in the previous year, the company posted $4.90 earnings per share. Amgen's revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.45 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's payout ratio is presently 70.15%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AMGN shares. Leerink Partners restated a "market perform" rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Barclays initiated coverage on shares of Amgen in a research note on Friday, February 20th. They set an "equal weight" rating and a $350.00 price target on the stock. Argus lifted their price target on shares of Amgen from $360.00 to $400.00 and gave the company a "buy" rating in a report on Friday, February 6th. Canaccord Genuity Group began coverage on shares of Amgen in a research note on Monday, April 20th. They set a "hold" rating and a $366.00 price objective for the company. Finally, Freedom Capital downgraded Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $357.12.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.